BIAL

December 9, 2021
img: Featured

Neurocrine Biosciences acquired the exclusive U.S. and Canadian rights to ONGENTYS® (opicapone) from Portela & CA, S.A. (BIAL) in 2017. In April 2020, ONGENTYS was approved by the U.S. Food and Drug Administration as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.